Davis Polk advised the underwriters in the initial public offering and listing on the Hong Kong Stock Exchange and the international offering in reliance on Rule 144A and Regulation S…
Davis Polk advised InnoCare Pharma Limited in connection with its initial public offering and listing on the Hong Kong Stock Exchange and an international offering in reliance on Rule 144A…
Davis Polk is advising Li & Fung Limited on its HK$7.22 billion ($926 million) proposed privatization by Golden Lincoln Holdings I Limited as the offeror by way of a scheme of…
Davis Polk advised Tianfeng Securities Co., Ltd. in connection with its $100 million notes offering. The notes will be consolidated and form a single series with the $200 million notes…
Davis Polk advised the dealers in connection with the establishment of $2 billion medium-term note program by China Cinda (2020) I Management Limited which is a wholly owned subsidiary of…
Davis Polk advised the initial purchasers in connection with a debut Regulation S offering by Zensun Enterprises Limited of $200 million 12.5% senior notes due 2022. The notes are…
Davis Polk advised the joint lead managers on a Regulation S offering by Xi’an Aerospace High-Tech Industry Development Co., Ltd, a company incorporated in the People’s Republic of China…
Davis Polk advised the initial purchasers in connection with a $225 million Regulation S only offering by China South City Holdings Limited of its 10.875% senior notes due 2022.
CSC is a…
Davis Polk advised the joint lead managers in connection with the Regulation S offering of $110 million principal amount of 12.5% senior notes due 2022 by Yango (Cayman) Investment Limited…
Davis Polk advised the sole placing agent for the placement of an aggregate of 90,000,000 ordinary shares in Hong Kong Television Network Limited for a total consideration of approximately…